GlassScriptPhysician profile
David Gary Polin
NPI 1588760011
$1,096.17
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.74 · 2022: $390 · 2023: $541 · 2024: $77.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $242.92 | 2022-2023 | Reactiv8 |
| Abbvie INC. | $204.26 | 2023-2024 | |
| Abbott Laboratories | $120.87 | 2023-2024 | Proclaim, Eterna, Ionicrf |
| Medtronic, INC. | $100.64 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $89.09 | 2022-2023 | Seglentis |
| Collegium Pharmaceutical, INC. | $70.24 | 2022-2023 | Xtampza |
| Saluda Medical Americas, INC. | $47.64 | 2023 | Evoke Scs |
| Amgen INC. | $41.00 | 2022 | |
| Masimo Corporation | $37.83 | 2023 | Set and Rainbow Set |
| Relievant Medsystems, INC. | $35.47 | 2022-2023 | Intracept |
| Ibsa Pharma INC. | $24.18 | 2023 | Tirosint, Licart |
| Lilly USA, LLC | $22.36 | 2022 | |
| Nevro Corp. | $17.24 | 2022 | |
| Protega Pharmaceutials INC | $16.49 | 2022 | |
| Pfizer INC. | $13.53 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Polin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.